Format

Send to

Choose Destination
Electrophoresis. 2012 Jul;33(12):1755-67. doi: 10.1002/elps.201100715.

Identifying cancer biomarkers by mass spectrometry-based glycomics.

Author information

1
Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409-1061, USA. yehia.mechref@ttu.edu

Abstract

Correlations between aberrant glycosylation and cancer have been established for decades. The major advances in mass spectrometry (MS) and separation science have rapidly advanced detailed characterization of the changes associated with cancer development and progression. Over the past 10 years, many reports have described MS-based glycomic methods directed toward comparing the glycomic profiles of different human specimens collected from disease-free individuals and patients with cancers. Glycomic profiling of glycoproteins isolated from human specimens originating from disease-free individuals and patients with cancers have also been performed. Profiling of native, labeled, and permethylated glycans has been acquired using MALDI-MS and LC-MS. This review focuses on describing, discussing, and evaluating the different glycomic methods employed to characterize and quantify glycomic changes associated with cancers of different organs, including breast, colon, esophagus, liver, ovarian, pancreas, and prostate.

PMID:
22740464
PMCID:
PMC3673023
DOI:
10.1002/elps.201100715
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center